Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

Annals of Oncology

Volumn 14, Issue 8, 2003, Pages 1291-1298

  Droz, J P ^a   Muracciole, X ^b   Mottet, N ^c   Ould Kaci, M ^d   Vannetzel, J M ^e   Albin, N ^f   Culine, S ^g   Rodier, J M ^h   Misset, J L ⁱ   Mackenzie, S ^j   Cvitkovic, E ^j   Benoit, G ^d  

^a CENTRE LÉON BÉRARD   (France)

^b TIMONE HOSPITAL   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

^e Clinique Hartman   (France)

^f CLINIQUE PASTEUR   (France)

^g Department of Oncology   (France)

^h BICHAT HOSPITAL   (France)

ⁱ HÔPITAL PAUL BROUSSE   (France)

^j Cvitkovic et Associes Consultants   (France)

more..

Author keywords

5 fluorouracil; DACH platinum; HRPC; Oxaliplatin

Indexed keywords

CAPECITABINE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUOROURACIL; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MITOXANTRONE; OXALIPLATIN; PREDNISONE; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DYSESTHESIA; FEBRILE NEUTROPENIA; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIDINES; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0042009659     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg342     Document Type: Article

References (28)

1. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29-35.
2. Scott R, Mutchnic D, Lajkowski T. Cancer of the prostate in elderly men; incidence, growth characteristics and clinical significance. J Urol Oncol 1969; 101: 602-607.
3. Small E, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15: 382-388.
4. Tannock IF, Osoba D, Stockler M et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian trial with palliative end point. J Clin Oncol 1996; 14: 1756-1764.
5. Berry W, Dakhil S, Modiano, M et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439-2443.
6. Dowling AJ, Tannock IF. Systemic treatment for prostate cancer. Cancer Treat Rev 1998; 24: 283-301.
7. Osoba D, Tannock IF, Ernst DS et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654-1663.
8. Pienta K, Redman B, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-2012.
9. Sitka CM, Ledakis P, Lynch J et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001; 28: 16-21.
10. Sinibaldi V, Carducci M, Moore-Cooper S et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-1465.
11. Hudes G, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 17: 958-967.
12. Petrylak D, Macarthur R, O'Connor J. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17: 958-967.
13. Eisenberger M, Simon R, O'Dwyer P. A re-evaluation of non-hormonal cytotoxic chemotherapy for prostate carcinoma. J Clin Oncol 1985; 3: 827-841.
14. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
15. Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 1997; 8: 876-885.
16. Kuzel T, Tallman M, Shevrin D et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center study. Cancer 1993; 72: 1965-1968.
17. Heim W, Ahlgren JD, Lokich J et al. Long term continuous infusion (CI) of 5-fluorouracil (5-FU) in treatment of metastatic prostate cancer: a phase II Mid-Atlantic Oncology Group (MAOP) study. Proc Am Soc Clin Oncol 1991; 10: 179 (Abstr).
18. Atkins J, Muss HB, Case D et al. High-dose 24 hour infusion of 5-fluorouracil in metastatic prostate cancer: a phase II trial of the Piedmont Oncology Association. J Clin Oncol 1996; 14: 526-529.
19. Huan S, Aitken S, Stewart DJ. 5-Fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study. Ann Oncol 1994; 5: 644-645.
20. Chen Y, Wang J, Fraig MM et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001; 61: 4112-4121.
21. Caussanel JP, Lévi F, Brienza S et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-1050.
22. Bubley G, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
23. Burris H, Moore M, Andersen J et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
24. Rougier P, Ducreux M, Ould Kaci M et al. Randomized Phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5-FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC). Proc Am Soc Clin Oncol 2000; 19: 262a (Abstr).
25. Scher H, Kelly W. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-1572.
26. Beer TM, Pierce WC, Lowe BA et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001; 12: 1273-1279.
27. Savarese DM, Halabi S, Hats V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-2516.
28. Lin CC, Hsu C-H, Chen J et al. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res 2001; 21: 1385-1390.